

## Cell Based Assays Market by Offering (Reagents, Assays Kits, Cell Lines, Microplates, Probes, Labels, Instruments & Software), Technology (Flowcytometry, HTS), Application (Drug Discovery (Toxicity, Pharmacokinetics), Research) - Global Forecast to 2029

Market Report | 2024-09-11 | 454 pages | MarketsandMarkets

### **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

## Report description:

The cell-based assays market is projected to reach USD 24.3 billion by 2029 from an estimated USD 17.3 billion in 2024, at a CAGR of 7.1% during the forecast period from 2024 to 2029. The growth of this market can be attributed to the increasing need of drug discovery and growing demand for cell-based assays in drug discovery. The rising R&D investments by pharmaceutical & biotechnology industries is propelling the growth of cell-based assays market. Also, growing incidences of cancer is promoting the need of advanced therapies resulting to boost the growth of cell-based assays market. Moreover, growing applications of cell-based assays in chronic diseases and personalized medicine is expected to propel the market growth in coming years.

"The drug discovery segment accounted for the largest share of by application segment in 2023."

Based on application, cell-based assays market is segmented into drug discovery, basic research, genetic studies, and other applications. Drug discovery segment is further categories into toxicity studies, pharmacokinetic studies, and pharmacodynamic studies. In 2023, the drug discovery segment accounted for the largest share of the global cell-based assays market by application. Increasing prevalence of cancer is driving the need of advanced thearpies resulting to promote segment's growth in the cell-based assays market. Additionally, increasing R&D investments, the introduction of new drugs, and the growing number of contract research organizations providing drug discovery services to pharmaceutical and biotechnology companies are also expected to drive to promote the segment's growth in cell-based assays market.

"The flow cytometry segment accounted for the major share by technology segment in 2023."

Based on technology, cell-based assays market is segmented into flow cytometry, high throughput screening, label free detection, and other technologies. In 2023, the flow cytometry segment accounted for the major share of the global cell-based assays

Scotts International. EU Vat number: PL 6772247784

market by technology. The growth of the flow cytometry segment is primarily attributed to the wide usage of flow cytometry for cell-based assays to perform multiple measurements. Additionally, growing adoption of advanced technologies for cell analysis and cell characterization is anticipated to boost the segment growth in cell-based assays market.

"The US has continued to dominate the cell-based assays market in 2023."

Based on the region, the cell-based assays market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, US dominated the cell-based assays market in North America. The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The US also has a strong healthcare infrastructure, which drives research and development in the life sciences sector. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of advanced cell-based therapies due to growing incidences of cancer is also driving the growth of the cell-based assays market.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 60% and Demand Side 40%
- -□By Designation: Managers 45%, CXO & Directors 30%, and Executives 25%
- By Region: North America 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa 5% List of Companies Profiled in the Report:
- -∏BD (US)
- Thermo Fisher Scientific Inc. (US)
- □ Danaher Corporation (US)
- -□Agilent Technologies, Inc. (US)
- Lonza (Switzerland)
- Charles River Laboratories (US)
- -□Bio-Rad Laboratories, Inc. (US)
- -□Revvity (US)
- -□Sartorius AG (Germany)
- -□Corning Incorporated (US)
- Promega Corporation (US)
- -□Cell Signaling Technology, Inc. (US)
- -□Eurofins Scientific (Luxembourg)
- -□Enzo Biochem, Inc. (US)
- -□Carna Biosciences, Inc. (Japan)
- -□Intertek Group plc (UK)
- -□BICO (Sweden)
- -□Cell Biolabs, Inc. (US)
- -□Reaction Biology (US)
- -□AAT Bioquest, Inc. (US)
- Pestka Biomedical Laboratories, Inc. (US)
- -□Neuromics (US)
- -∏BPS Bioscience, Inc. (US)
- -□BellBrook Labs (US)
- Profacgen (US)
- -□BMG LABTECH (Germany)
- Hanugen Theraputics (India)

Scotts International, EU Vat number: PL 6772247784

¬Altogen Labs (US)

-□BioAgilytix (US)

Research Coverage:

This research report categorizes the cell-based assays market by offering (consumables (reagents, assay kits (reporter gene assays, cell growth assays, second messenger assays, cell death assays, and other assay kits), microplates, cell line (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables), instruments, software, and services, technology (flow cytometry, high throughput screening, label-free detection, and other technologies), application (drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications), end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell-based assays market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, surge in cases of cancer, and increasing R&D investments and fundings for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market
- Market Development: Comprehensive information about lucrative markets the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market
- Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Theraputics (India), Altogen Labs (US), and BioAgilytix (US), among others in the market.

### **Table of Contents:**

1⊓INTRODUCTION⊓37

- 1.1□STUDY OBJECTIVES□37
- 1.2 | MARKET DEFINITION | 37
- 1.3∏STUDY SCOPE∏38
- 1.3.1 MARKETS COVERED 38
- 1.3.2 INCLUSIONS & EXCLUSIONS 39
- 1.3.3 YEARS CONSIDERED 39
- 1.3.4□CURRENCY CONSIDERED□39

Scotts International, EU Vat number: PL 6772247784

- 1.4∏STAKEHOLDERS∏40
- 1.5 SUMMARY OF CHANGES 40
- 2 RESEARCH METHODOLOGY 41
- 2.1 RESEARCH DATA 41
- 2.1.1□SECONDARY DATA□42
- 2.1.2 PRIMARY DATA □ 43
- 2.2 MARKET ESTIMATION METHODOLOGY 44
- 2.2.1 BOTTOM-UP APPROACH 44
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 47
- 2.2.3 TOP-DOWN APPROACH 47
- 2.3 MARKET GROWTH RATE PROJECTIONS ☐ 48
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 50
- 2.5 □ RESEARCH ASSUMPTIONS □ 51
- 2.6 RISK ANALYSIS 51
- 2.7 LIMITATIONS 51
- 3 EXECUTIVE SUMMARY 53
- 4□PREMIUM INSIGHTS□57
- 4.1 CELL-BASED ASSAYS MARKET OVERVIEW 57
- 4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2023) 58
- 4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2023 □ 59
- 4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2023 59
- 4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
- 5∏MARKET OVERVIEW∏61
- 5.1□INTRODUCTION□61
- 5.2 MARKET DYNAMICS 61
- 5.2.1 DRIVERS 63
- 5.2.1.1 ☐ Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery ☐ 63
- 5.2.1.2 Government support and funding for cell-based research 64
- 5.2.1.3 Growing efforts to curtail animal-based studies 65
- 5.2.1.4 Rising prevalence of cancer 65
- 5.2.1.5 Alliances to accelerate innovations in drug discovery 67
- 5.2.2 RESTRAINTS 67
- 5.2.2.1 High cost of instruments and restrictions imposed by product end-user licenses for reagents 67
- 5.2.2.2 Lack of standardization of protocols used in cell-based assays 68
- 5.2.3 OPPORTUNITIES 69
- 5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine 69
- 5.2.3.2 Growth opportunities in emerging economies 70
- 5.2.3.3 Rising adoption of AI in drug discovery and cell analysis 71
- $5.2.4 \verb||CHALLENGES|||71$
- 5.2.4.1 Complexities in assay designs 71
- 5.2.4.2 Shortage of skilled professionals 71
- 5.3 TECHNOLOGY ANALYSIS 72
- 5.3.1 KEY TECHNOLOGIES 72
- 5.3.1.1 Flow Cytometry 72
- 5.3.1.2 High-throughput screening 73
- 5.3.1.3 High-content screening 73
- 5.3.1.4 Label-free detection 73

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 5.3.2 COMPLEMENTARY TECHNOLOGIES 74
- 5.3.2.1 Artificial intelligence and machine learning 74
- 5.3.3 ADJACENT TECHNOLOGIES 74
- 5.3.3.1 Nanotechnology 74
- 5.4 SUPPLY CHAIN ANALYSIS 74
- 5.5 VALUE CHAIN ANALYSIS 76
- 5.6 PRICING ANALYSIS 77
- 5.7 ECOSYSTEM ANALYSIS 78
- 5.7.1 RAW MATERIAL VENDORS 79
- 5.7.2 PRODUCT/SERVICE VENDORS 79
- 5.7.3∏END USERS∏80
- 5.7.4 REGULATORY BODIES 81
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 181
- 5.9 PATENT ANALYSIS 82
- 5.9.1 PATENT METHODOLOGY 82
- 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024 R82
- 5.9.3 INNOVATION & PATENT APPLICATIONS 183
- 5.9.4 TOP APPLICANTS 83
- 5.10 KEY CONFERENCES & EVENTS, 2024-2025 86
- 5.11 ⊓ REGULATORY LANDSCAPE ∏ 87
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
- 5.11.2 REGULATORY SCENARIO 91
- 5.12 PORTER'S FIVE FORCES ANALYSIS 94
- 5.12.1 THREAT OF NEW ENTRANTS 95
- 5.12.2 THREAT OF SUBSTITUTES 95
- 5.12.3 BARGAINING POWER OF SUPPLIERS 95
- 5.12.4 BARGAINING POWER OF BUYERS 95
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY □95
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 96
- 5.13.1 TKEY STAKEHOLDERS IN BUYING PROCESS 196
- 5.13.2 BUYING CRITERIA 97
- 5.14 INVESTMENT & FUNDING SCENARIO □98
- 5.15⊓TRADE ANALYSIS□99
- 5.16 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET 102
- 6 CELL-BASED ASSAYS MARKET, BY OFFERING 103
- 6.1□INTRODUCTION□104
- 6.2□CONSUMABLES□104
- 6.2.1 REAGENTS 109
- 6.2.1.1 High demand for reagents in research applications to propel market growth 109
- 6.2.2∏ASSAY KITS∏113
- 6.2.2.1 Reporter gene assays 117
- 6.2.2.1.1 □Versatility of reporter gene assays and widespread applications to fuel growth □117
- 6.2.2.2 Cell growth assays 121
- 6.2.2.2.1 ∏Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market ☐ 121
- 6.2.2.3 Second messenger assays 125
- 6.2.2.3.1 ☐ Adoption of secondary messenger assays for cell signaling studies to fuel growth ☐ 125
- 6.2.2.4 Cell death assays 129

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 6.2.2.4.1 | Importance of cell death quantification in drug development to favor growth | 129 6.2.2.5 | Other assay kits | 132 6.2.3 | MICROPLATES | 136
- 6.2.3.1 Demand for microplates in assay development to drive market 136
- 6.2.4 CELL LINES 139
- 6.2.4.1∏Immortalized cell lines∏143
- 6.2.4.1.1 Wide use of immortalized cell lines to boost market 143

?

- 6.2.4.2 Primary cell lines 146
- 6.2.4.2.1 ☐ Advantages in drug development, preclinical research, and other applications to propel market ☐ 146
- 6.2.4.3 Stem cell lines 150
- 6.2.4.3.1 Rising use in tissue and disease models to fuel adoption 150
- 6.2.5 PROBES & LABELS 154
- 6.2.5.1 Growing need for effective cell labeling to boost demand 154
- 6.2.6 OTHER CONSUMABLES 157
- 6.3∏INSTRUMENTS∏161
- 6.3.1 □ AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH □ 161
- 6.4□SERVICES□165
- 6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH 165
- 6.5∏SOFTWARE∏168
- 6.5.1□INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH□168
- 7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY 172
- 7.1∏INTRODUCTION∏173
- 7.2 FLOW CYTOMETRY 173
- 7.2.1∏WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET∏173
- 7.3 HIGH-THROUGHPUT SCREENING 177
- 7.3.1∏INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH∏177
- 7.4⊓LABEL-FREE DETECTIONП180
- 7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND 180
- 7.5∏OTHER TECHNOLOGIES∏184
- 8□CELL-BASED ASSAYS MARKET, BY APPLICATION□187
- 8.1∏INTRODUCTION∏188
- 8.2 DRUG DISCOVERY 188
- 8.2.1 TOXICITY STUDIES 192
- 8.2.1.1∏Increasing demand for cell-based assays in toxicity testing to fuel growth∏192
- 8.2.2 PHARMACOKINETIC STUDIES 196
- 8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays 196
- 8.2.3 PHARMACODYNAMIC STUDIES 200
- 8.2.3.1 Advantages of cell-based assays in pharmacodynamics to propel growth 200
- 8.3 BASIC RESEARCH 204
- 8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES 204

?

- 8.4 GENETIC STUDIES 208
- 8.4.1 | INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET | 208
- $8.5 \square OTHER APPLICATIONS \square 211$
- 9□CELL-BASED ASSAYS MARKET, BY END USER□215

### Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 9.1 INTRODUCTION 216
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 216
- 9.2.1∏PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET∏216
- 9.3 CONTRACT RESEARCH ORGANIZATIONS 221
- 9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH 221
- 9.4 ACADEMIC & RESEARCH INSTITUTES 225
- 9.4.1 ⊓RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET ☐ 225
- 10 CELL-BASED ASSAYS MARKET, BY REGION 229
- 10.1 INTRODUCTION 230
- 10.2 NORTH AMERICA 230
- 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 231
- 10.2.2∏US∏236
- 10.2.2.1 □US to dominate North American cell-based assays market during forecast period □236
- 10.2.3 CANADA 240
- 10.2.3.1 Increasing funding and investments to drive market in Canada 240
- 10.3 EUROPE 243
- 10.3.1 EUROPE: MACROECONOMIC OUTLOOK 244
- 10.3.2 GERMANY 248
- 10.3.2.1 Germany to dominate cell-based assays market in Europe 248
- 10.3.3∏UK∏252
- 10.3.3.1 Growing cancer research funding to increase demand for cell-based assays 252
- 10.3.4 FRANCE 256
- 10.3.4.1 Growing biotechnology sector to drive market 256
- 10.3.5 | ITALY | 260
- 10.3.5.1 Growing pharmaceutical industry in Italy to boost market 260
- 10.3.6 SPAIN 263
- 10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth 263
- 10.3.7 REST OF EUROPE 267
- 10.4□ASIA PACIFIC□270
- 10.4.1 ☐ ASIA PACIFIC: MACROECONOMIC OUTLOOK ☐ 271
- 10.4.2 CHINA 276
- 10.4.2.1 ☐ Increasing R&D expenditure to favor market growth ☐ 276
- 10.4.3⊓IAPAN⊓280
- 10.4.3.1 Government initiatives for drug innovation to support market growth 280
- 10.4.4□INDIA□283
- 10.4.4.1 | Increasing investments in R&D and funding for life science research to propel market | 283
- 10.4.5∏AUSTRALIA∏287
- 10.4.5.1 Booming life science sector to propel market 287
- 10.4.6 SOUTH KOREA 290
- 10.4.6.1 Increasing strategic alliances to support market growth 290
- 10.4.7 REST OF ASIA PACIFIC 294
- 10.5 LATIN AMERICA 298
- 10.5.1 | LATIN AMERICA: MACROECONOMIC OUTLOOK | 299
- 10.5.2∏BRAZIL∏303
- 10.5.2.1 Brazil to hold largest share of Latin American market 303
- 10.5.3 MEXICO 307
- 10.5.3.1 Government support for biopharmaceutical production to support market growth 307

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 10.5.4 REST OF LATIN AMERICA 310
- 10.6 MIDDLE EAST 314
- 10.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 315
- 10.6.2 GCC COUNTRIES 318
- 10.6.2.1∏Saudi Arabia∏322
- 10.6.2.1.1 Increasing R&D investments to drive market 322
- 10.6.2.2∏UAE∏326
- 10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities 326
- 10.6.2.3 Rest of GCC Countries 330
- 10.6.3 REST OF MIDDLE EAST 333
- 10.7 | AFRICA | 337
- 10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH 337
- 10.7.2 AFRICA: MACROECONOMIC OUTLOOK 338
- 11 COMPETITIVE LANDSCAPE 342
- 11.1□OVERVIEW□342
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 342
- 11.2.1∏OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL-BASED ASSAYS MARKET∏342
- 11.3 REVENUE ANALYSIS 345
- 11.4 MARKET SHARE ANALYSIS 346
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 348
- 11.5.1 STARS 348
- 11.5.2 EMERGING LEADERS 348
- 11.5.3 PERVASIVE PLAYERS 348
- 11.5.4 PARTICIPANTS 348
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 350
- 11.5.5.1 Company footprint 350
- 11.5.5.2 Offering footprint 351
- 11.5.5.3 Technology footprint 352
- 11.5.5.4 Application Footprint 353
- 11.5.5.5 Region footprint 354
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 355
- 11.6.1 □ PROGRESSIVE COMPANIES □ 355
- 11.6.2 □ RESPONSIVE COMPANIES □ 355
- 11.6.3 DYNAMIC COMPANIES □355
- 11.6.4□STARTING BLOCKS□355
- 11.6.5□COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023□357
- 11.7 VALUATION AND FINANCIAL METRICS 359
- 11.8 BRAND/PRODUCT COMPARISON 360
- 11.9 COMPETITIVE SCENARIO 361
- 11.9.1 ☐ PRODUCT/SERVICE LAUNCHES & APPROVALS ☐ 361
- 11.9.2 DEALS 362
- 11.9.3 EXPANSIONS 363
- 12□COMPANY PROFILES□364
- 12.1 INTRODUCTION 364
- 12.2 KEY PLAYERS 364
- 12.2.1 DANAHER CORPORATION 364
- 12.2.1.1 Business overview 364

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.1.2 Products/Services offered 365
- 12.2.1.3 Recent developments 369
- 12.2.1.3.1 Deals 369
- 12.2.1.3.2 Expansions 369
- 12.2.1.4 MnM view 370
- 12.2.1.4.1 Key strengths 370
- 12.2.1.4.2 Strategic choices 370
- 12.2.1.4.3 Weaknesses & competitive threats 370
- 12.2.2 THERMO FISHER SCIENTIFIC INC. 371
- 12.2.2.1 Business overview 371
- 12.2.2.2 Products/Services offered □ 373
- 12.2.2.3 Recent developments 377
- 12.2.2.3.1 Deals 377
- 12.2.2.3.2 | Expansions | 377
- 12.2.2.4 MnM view 378
- 12.2.2.4.1 Key strengths 378
- 12.2.2.4.2 Strategic choices 378
- 12.2.2.4.3 Weaknesses and competitive threats 378
- 12.2.3 MERCK KGAA 379
- 12.2.3.1 Business overview 379
- 12.2.3.2 Products/Services offered 380
- 12.2.3.3 Recent developments 383
- 12.2.3.3.1 Deals 383
- 12.2.3.3.2 | Expansions | 384
- 12.2.3.4 MnM view 384
- 12.2.3.4.1 Key strengths 384
- 12.2.3.4.2 Strategic choices 384
- 12.2.3.4.3 Weaknesses and competitive threats 384
- 12.2.4 BD 385
- 12.2.4.1 Business overview 385
- 12.2.4.2 Products/Services offered 386
- 12.2.4.3 Recent developments 389
- 12.2.4.3.1 Product launches □ 389
- 12.2.4.3.2∏Deals∏389
- 12.2.4.4 MnM view 390
- 12.2.4.4.1 Key strengths 390
- 12.2.4.4.2 Strategic choices 390
- 12.2.4.4.3 Weaknesses and competitive threats 390
- 12.2.5 AGILENT TECHNOLOGIES, INC. 391
- 12.2.5.1 Business overview 391
- 12.2.5.2 Products/Services offered 392
- 12.2.5.3 Recent developments 393
- 12.2.5.3.1 Product launches 393
- 12.2.5.4 MnM view 394
- 12.2.5.4.1 | Key strengths | 394
- 12.2.5.4.2 Strategic choices 394
- 12.2.5.4.3 Weaknesses & competitive threats 394

- 12.2.6 LONZA 395
- 12.2.6.1 Business overview 395
- 12.2.6.2 Products/Services offered 397
- 12.2.6.3 Recent developments 398
- $12.2.6.3.1 \square Deals \square 398$
- 12.2.6.3.2 Expansions 398
- 12.2.7□EUROFINS SCIENTIFIC□399
- 12.2.7.1 Business overview 399
- 12.2.7.2 Products/Services offered 400
- 12.2.7.3 Recent developments 402
- 12.2.7.3.1 Deals 402

?

- 12.2.8 CHARLES RIVER LABORATORIES 403
- 12.2.8.1 Business overview 403
- 12.2.8.2 Products/services offered 404
- 12.2.8.3 Recent developments 406
- 12.2.8.3.1 Service launches 406
- 12.2.8.3.2 Deals 406
- 12.2.9 BIO-RAD LABORATORIES, INC. 408
- 12.2.9.1 Business overview 408
- 12.2.9.2 Products/Services offered 410
- 12.2.10 REVVITY 411
- 12.2.10.1 Business overview 411
- 12.2.10.2 Products/Services offered 412
- 12.2.10.3 Recent developments 414
- 12.2.10.3.1 Product launches 414
- 12.2.11 SARTORIUS AG 415
- 12.2.11.1 Business overview 415
- 12.2.11.2 Products/Services offered 416
- 12.2.11.3 Recent developments 417
- 12.2.11.3.1 Expansions 417
- 12.2.12 CORNING INCORPORATED 418
- $12.2.12.1 \verb|| Business overview \verb||| 418$
- 12.2.12.2 Products/Services offered 419
- 12.2.13 PROMEGA CORPORATION 420
- 12.2.13.1 Business overview 420
- 12.2.13.2 Products/Services offered 420
- 12.2.14 CELL SIGNALING TECHNOLOGY, INC. 422
- 12.2.14.1 Business overview 422
- $12.2.14.2 \verb||Products/Services| offered \verb||| 422$
- 12.2.15 ENZO BIOCHEM INC. 424
- 12.2.15.1 Business overview 424
- 12.2.15.2 Products/Services offered 425
- 12.2.15.3 Recent developments 427
- 12.2.15.3.1 Expansions 427
- 12.2.16□CARNA BIOSCIENCES, INC.□428
- 12.2.16.1 Business overview 428

### Scotts International. EU Vat number: PL 6772247784

- 12.2.16.2 Products/Services offered 429
- 12.2.17 INTERTEK GROUP PLC 431
- 12.2.17.1 Business overview 431
- 12.2.17.2 Products/services offered 432
- 12.2.18 BICO 433
- 12.2.18.1 Business overview 433
- 12.2.18.2 Products/Services offered 434
- 12.3 OTHER PLAYERS 435
- 12.3.1 CELL BIOLABS, INC. 435
- 12.3.2 REACTION BIOLOGY 1436
- 12.3.3 AAT BIOQUEST, INC. 437
- 12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC. 438
- 12.3.5 NEUROMICS 439
- 12.3.6 BPS BIOSCIENCE, INC. 439
- 12.3.7 BELLBROOK LABS 440
- 12.3.8∏PROFACGEN∏441
- 12.3.9 BMG LABTECH 441
- 12.3.10 HANUGEN THERAPEUTICS 442
- 12.3.11 ALTOGEN LABS 443
- 12.3.12 BIOAGILYTIX 444
- 13 DISCUSSION GUIDE 445
- 13.1  $\square$ KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL  $\square$ 450
- 13.2□CUSTOMIZATION OPTIONS□452
- 13.3 RELATED REPORTS 452
- 13.4 AUTHOR DETAILS 453



To place an Order with Scotts International:

Complete the relevant blank fields and sign

☐ - Print this form

# Cell Based Assays Market by Offering (Reagents, Assays Kits, Cell Lines, Microplates, Probes, Labels, Instruments & Software), Technology (Flowcytometry, HTS), Application (Drug Discovery (Toxicity, Pharmacokinetics), Research) - Global Forecast to 2029

Market Report | 2024-09-11 | 454 pages | MarketsandMarkets

<ul> <li>Send as a scanned email to support@scotts-international.com</li> </ul>					
ORDER FORM:					
Select license	License		Price		
	Single User		\$4950.00		
	Multi User		\$6650.00		
	Corporate License	\$8150.00			
	Enterprise Site License		\$10000.00		
		VAT			
		Total			
*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.  [** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers					
Email*		Phone*			
First Name*		Last Name*			
Job title*					
Company Name* [		EU Vat / Tax ID / NIP number*			
Address*		City*			

Scotts International. EU Vat number: PL 6772247784

Zip Code*	Country*	
	Date	2025-06-25
	Signature	